AKRO — Akero Therapeutics Income Statement
0.000.00%
Last trade - 00:00- $1.42bn
- $895.03m
- 41
- 26
- 62
- 39
Annual income statement for Akero Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Total Revenue | 0 | 0 | 0 | 0 | 0 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Total Operating Expenses | 45.7 | 80.2 | 101 | 115 | 173 |
| Operating Profit | -45.7 | -80.2 | -101 | -115 | -173 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -43.8 | -79.2 | -101 | -112 | -152 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -43.8 | -79.2 | -101 | -112 | -152 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -43.8 | -79.2 | -101 | -112 | -152 |
| Adjustments to Net Income | |||||
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -43.8 | -79.2 | -101 | -112 | -152 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -2.9 | -2.52 | -2.89 | -2.87 | -2.89 |